Cerebral edema in DKA

Background

• Most feared complication of pediatric DKA; accounts for 50-65% of all DKA deaths
• Occurs in 0.5-1% of pediatric DKA episodes (up to 4-5% with subclinical edema on imaging)
• Mortality rate: 21-24%; significant neurologic morbidity (10-26%) in survivors
• Almost all affected patients are <20 years old
• Mental status abnormalities (GCS <14) occur in 4-15% of children treated for DKA and are often associated with mild cerebral edema on imaging

Pathophysiology

• Previously attributed to osmotic shifts with rapid IV fluid administration; this model has been largely disproven
• Current understanding favors cerebral hypoperfusion and reperfusion injury during DKA treatment as the primary mechanism
• Cerebral edema has been found on imaging even before treatment is initiated, including in children found dead at home from undiagnosed DKA
• Bicarbonate administration is independently associated with cerebral edema (persists after correcting for DKA severity) — avoid bicarbonate in pediatric DKA

Risk Factors

• Age <5 years
• New-onset diabetes (first DKA presentation)
• Severe acidosis (pH <7.1, pCO₂ <20)
• Higher BUN at presentation (marker of dehydration severity)
• Failure of corrected sodium to rise with treatment
• Severe hyperosmolality
• Bicarbonate administration
• Late presentation for medical evaluation
• Previous episodes of DKA
• Overaggressive fluid resuscitation is NOT a proven risk factor — the PECARN FLUID trial (1,389 episodes) showed neither fluid rate nor sodium content significantly affected neurologic outcomes

Clinical Features

• Typically begins 4-12 hours after onset of therapy, but may occur before treatment or up to 48 hours later
  • Many children appear to be improving from DKA before deteriorating from cerebral edema
  • Can occur at presentation in new-onset diabetes (including type 2)

Warning Signs (use Muir Criteria for early detection)

Diagnostic criteria (any ONE is diagnostic):

• Abnormal motor or verbal response to pain
• Decorticate or decerebrate posture
• Cranial nerve palsy (especially III, IV, VI)
• Abnormal neurogenic respiratory pattern (grunting, tachypnea, Cheyne-Stokes, apneusis)

Major criteria:

• Altered mentation / fluctuating level of consciousness
• Sustained heart rate deceleration (>20 bpm decrease) not attributable to improved intravascular volume or sleep
• Age-inappropriate incontinence

Minor criteria:

• Vomiting
• Headache
• Lethargy or difficulty arousing
• Diastolic BP >90 mmHg
• Age <5 years

Interpretation: 1 diagnostic criterion, OR 2 major criteria, OR 1 major + 2 minor criteria → 92% sensitivity and 96% specificity for cerebral edema

• GCS alone is not sensitive enough — use the Muir criteria above
• Perform a thorough baseline neurologic exam (including cranial nerves) at presentation and document it so colleagues can identify changes

Differential Diagnosis

Hyperglycemia

Diabetic Emergencies

• Diabetic ketoacidosis (DKA)
• Diabetic ketoacidosis (peds)
• Hyperosmolar hyperglycemic state (HHS)
• Nonketotic hyperglycemia
• Euglycemic DKA (SGLT-2 inhibitors, pregnancy, fasting)

Diabetes Mellitus (New or Known)

• Type 1 diabetes mellitus (new-onset or uncontrolled)
• Type 2 diabetes mellitus (new-onset or uncontrolled)
• Medication noncompliance or insulin pump malfunction
• Gestational diabetes
• Latent autoimmune diabetes of adults (LADA)

Medication/Drug-Induced

• Corticosteroids (most common drug-induced cause)
• Thiazide diuretics
• Atypical antipsychotics (olanzapine, clozapine, quetiapine)
• Beta-blockers (especially non-selective)
• Phenytoin
• Tacrolimus, cyclosporine (transplant patients)
• Protease inhibitors (HIV antiretrovirals)
• Catecholamines (epinephrine, norepinephrine infusions)
• SGLT-2 inhibitors (paradoxical DKA with euglycemia)
• Total parenteral nutrition (TPN)
• Dextrose-containing IV fluids (iatrogenic)
• Niacin
• Pentamidine (initially hyperglycemia, then hypoglycemia from beta-cell destruction)

Physiologic Stress Response

• Sepsis / critical illness (stress hyperglycemia — very common in the ED)
• Trauma / major surgery / burns
• Acute coronary syndrome / myocardial infarction
• Stroke (especially hemorrhagic)
• Pancreatitis (both a cause and consequence)
• Shock (any etiology)
• Pain (catecholamine surge)
• Seizure (postictal)
• Physiologic stress alone rarely causes glucose >200 mg/dL in non-diabetics; glucose >200 in a "stress response" should prompt evaluation for undiagnosed diabetes or prediabetes

Endocrine

• Cushing syndrome / Cushing disease (cortisol excess)
• Pheochromocytoma (catecholamine excess)
• Hyperthyroidism / thyroid storm
• Acromegaly (growth hormone excess)
• Glucagonoma (rare)
• Somatostatinoma (rare)

Pancreatic

• Pancreatitis (acute or chronic — destruction of islet cells)
• Pancreatic malignancy (adenocarcinoma, neuroendocrine tumors)
• Post-pancreatectomy
• Cystic fibrosis-related diabetes
• Hemochromatosis (iron deposition in pancreas — "bronze diabetes")

Toxic/Overdose

• Iron toxicity (hepatic injury → impaired glucose regulation)
• Salicylate toxicity (can cause both hyper- and hypoglycemia)
• Sympathomimetic toxicity (cocaine, methamphetamine)
• Calcium channel blocker toxicity (impairs insulin secretion)
• Carbon monoxide toxicity (stress response)

Other

• Renal failure (chronic kidney disease, acute kidney injury — impaired insulin clearance AND insulin resistance)
• Cirrhosis / hepatic failure (impaired glycogenolysis regulation)
• Pregnancy (gestational diabetes, steroid administration for fetal lung maturity)
• Parenteral nutrition (TPN, dextrose-containing fluids)
• Post-transplant diabetes (immunosuppressants)

Complications of Diabetes (Not Causes of Hyperglycemia)

These are associated conditions that may be present alongside hyperglycemia but do not themselves cause elevated glucose:

• Diabetic foot infection
• Diabetic peripheral neuropathy
• Cerebral edema in DKA
• Diabetic retinopathy
• Diabetic nephropathy

• Also consider: hypoglycemia (most important to rule out first), cerebral venous thrombosis, intracranial hemorrhage, stroke

Evaluation

• Cerebral edema in DKA is a CLINICAL diagnosis — do NOT delay treatment for imaging
• Capillary glucose measurement immediately to rule out hypoglycemia as the cause of altered mental status
• Head CT (non-contrast) — obtain after treatment has been initiated, NOT before
  • CT may be normal early (sensitivity is limited); used primarily to rule out other pathology (hemorrhage, thrombosis)
  • CT may show diffuse cerebral edema, small ventricles, or loss of sulcal markings
• Monitor corrected sodium during DKA treatment — failure of corrected sodium to rise as glucose falls suggests excess free water and increased risk
  • Corrected Na = Measured Na + [1.6 × (glucose – 100) / 100]

Monitoring During DKA Treatment (Prevention)

• Hourly neurologic assessments for the first 12 hours of DKA therapy (minimum), including cranial nerves
  • Increase frequency to q30min in children <5 years or with pH <7.1
• Avoid bicarbonate administration
• Follow corrected sodium — should trend upward during treatment

Management

Treat IMMEDIATELY when suspected — do not wait for imaging

Immediate Actions

• Elevate head of bed to 30 degrees
• Reduce IVF rate by one-third
• Avoid intubation unless absolutely necessary (loss of hyperventilatory drive worsens cerebral edema)
  • If intubation is required, maintain pCO₂ near pre-intubation level — avoid aggressive hyperventilation (associated with worse outcomes)

Hyperosmolar Therapy

• Give whichever agent is immediately available — do NOT delay treatment
• Mannitol 0.5-1 g/kg IV over 20 minutes
  • May repeat in 30 min to 2 hours if inadequate response
  • Historically the most commonly used agent; best studied in this specific population
  • Disadvantage: causes osmotic diuresis (may worsen dehydration)
• 3% Hypertonic saline 3-5 mL/kg (or 250 mL) IV over 15-30 minutes
  • Increasingly used in pediatric ICU settings
  • One retrospective study (DeCourcey 2013) found hypertonic saline as sole agent was associated with higher mortality than mannitol alone (OR 2.71), though this had significant limitations
• If initial therapy is ineffective, give the other agent (i.e., if mannitol given first, try 3% saline; and vice versa)

Additional Measures

• Consult neurosurgery and PICU/ICU immediately
• Treat noncardiogenic pulmonary edema if present
• Hold insulin infusion during acute treatment of cerebral edema (the priority shifts to managing intracranial pressure)
• Consider ICP monitoring in consultation with neurosurgery

Disposition

• Admit PICU/ICU — all patients
• Mortality remains high (21-24%) even with treatment; early recognition and treatment provides the best chance for good outcomes

Pearls

• Cerebral edema is a CLINICAL diagnosis — treat first, image after
• Use the Muir criteria (not just GCS) for early detection — 92% Sn, 96% Sp
• Perform and document a thorough neuro exam at the start of DKA treatment so changes can be identified
• The old dogma that "rapid IVF causes cerebral edema" has been disproven by the PECARN FLUID trial
• Never give bicarbonate in pediatric DKA — it is an independent risk factor for cerebral edema
• Give whichever osmolar agent (mannitol or 3% saline) is immediately available — do not delay searching for one over the other
• If you must intubate, match the pre-intubation pCO₂ — iatrogenic normalization of CO₂ worsens cerebral edema
• A child improving from DKA who suddenly deteriorates = cerebral edema until proven otherwise

See Also

• Diabetes mellitus (main)
• DKA
• DKA (Peds)
• Cerebral edema
• Herniation syndromes